June 18, 2018

What Are Analysts Report About Repros Therapeutics Inc. (RPRX)

12 October 2017, 05:08 | Melvin Schneider

Repros Therapeutics (NASDAQ:RPRX) shares traded on 41.51% above secure line and closed at $0.75. RPRX has diverse figures for different time frames; starting from week's performance it has positive performance of 104.73% in last five regular trading sessions. It has a market cap of $27.26 Million. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 2.23% with $36.34 Million sitting short, betting on future declines.

Taking a broader look brokerage firms' analysts on the street with an expectant view have Repros Therapeutics (NASDAQ:RPRX) high price target of $5.5 and with a conservative view have low price target of $5.5. Looking at the stock's movement on the chart, Repros Therapeutics Inc. recorded a 52-week high of $2.18. The latest exchange of 2.85 Million shares is below its average trading activity of 291.76 Million shares. Unusual volume shows something has likely happened in the stock-such as a news release or traders have become anxious or euphoric about the stock's potential. However, 149.58% over the last one month, 35.33% for the last quarter and year to date performance stands at -43.18%. The stock realized a fall in short interest between August 31, 2017 and September 15, 2017 of -32.24%. Share performance for the month is now at -54.50%. Its weekly performance showed upward trend of 65.63 percent. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. The percentage of shares being held by the company management was 0.2% while institutional stake was 20.1%.

Liquidity ratios help investors to determine a company's ability to pay off its debts. Its book value per share for the most recent quarter is $-0.01 while its price to book ratio for the same period is 0, as for as the company's cash per share for the most recent quarter is $0.1, however its price to cash per share ratio for the same period is 6.64.

Repros Therapeutics Inc. (RPRX) has a Return on Assets of -212.1 percent, Return on Investment of 0 percent and a Return on Equity of -412.4 percent. The 50 day moving average moved up $0.30 whereas the 200 day average was up by +13.7721%.

The company's diluted EPS for trailing twelve months was -0.63. Revenue during the quarter was $39.84 billion, representing -2% growth from $40.52 billion in year-ago quarter.

Arsene Wenger: I could sell Mesut Ozil and Alexis Sanchez in January
After Brazil's 3-0 win over Chile this week, Alves said: "He is wanted by many teams". I hope he'll be happy, wherever he goes.

JPMorgan earnings are coming - here's what Wall Street expects
Its up 0.32, from 0.87 in 2017Q1. 26 funds opened positions while 79 raised stakes. (NYSE:JPM) for 428,492 shares. The Firm operates through two lines of business: Investment Servicing and Investment Management.

VVPAT to be Used For Himachal Pradesh Assembly Polls: Election Commission
The Election Commissioner said, " Model code of conduct for Himachal Pradesh assembly election comes into effect from now itself". As far as practical, polling stations are being made disabled-friendly, so that they can exercise their franchise.

RPRX's mean Piotroski F-Score: 3 in the past 7 years. A rating of 4 or 5 would represent a Sell recommendation.

Quarterly Earnings Growth on year-over-year basis stands at 56 percent. The company posted an earnings surprise of 63.6%.

This company has been competing with others in the Healthcare space and offers its own combination of interesting factors Repros Therapeutics Inc. The typical day in the last two weeks has seen about a 16.33% volatility. On average, analysts predict that Repros Therapeutics will post ($0.76) EPS for the current fiscal year.

The clinical development expenses pertaining to enclomiphene dropped for the reported quarter as against the prior year period, due to lower expenses related with its Phase II proof of concept trial, ZA-205. (RPRX)-0 analysts issued Buy for the stock, 1 analysts gave Outperform rating, 0 think it's a Hold, 0 issued Underperform, while 0 analyst gave a Sell rating. If Repros Therapeutics Inc. However, the institutional investors are observed to own 20.10% of the total shares.

Other News

Trending Now

Arsene Wenger: 'Jack Wilshere showing best form for a long time'
The Gunners star, 25, last played for the Three Lions in the disastrous 2-1 loss to Iceland in the Euro 2016 knockout stage. Arsenal acquired "world class" talent in Alexandre Lacazette and a "monster" in Sead Kolasinac , says Jack Wilshere .

Trump Attacks Puerto Rico, Threatens To Pull Emergency Responders
More shipments of supplies donated by New Yorkers and a top state official are being sent to Puerto Rico, Gov. Weeks after Maria made landfall, 84 percent of Puerto Ricans don't have power.

Garber takes over the role from David Hyde Pierce (with Peters stepping in for Bette Midler.) His first show is January 20. " DC's Legends of Tomorrow " season 3 may be the final regular season for one of the show's main cast members.

SC reserves verdict on passive euthanasia
The court was hearing a petition seeking that the right to die with dignity should be declared a fundamental right. Justice Chandrachud suggested a two-pronged test on when a living will take effect.